Summary of the best evidence for the management of patients with hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy
10.3969/j.issn.1008-794X.2025.08.016
- VernacularTitle:经肝动脉灌注化疗肝癌患者管理的最佳证据
- Author:
Yan JI
1
;
Yi WANG
;
Xin LIN
;
Junying HUANG
;
Qian ZHONG
;
Meng WANG
;
Li LI
Author Information
1. 200082 上海 海军军医大学第三附属医院重症医学科
- Keywords:
hepatic arterial infusion chemotherapy;
patient with hepatocellular carcinoma;
evidence-based nursing;
evidence summary
- From:
Journal of Interventional Radiology
2025;34(8):888-893
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate and summarize the best evidence for the management of patients with hepatocellular carcinoma(HCC)receiving hepatic arterial infusion chemotherapy(HAIC),so as to provide evidence-based basis for guiding clinical nursing practice.Methods According to the"6S"evidence model,a computerized retrieval of domestic and foreign academic papers concerning the management of HCC patients receiving HAIC,including guidelines,clinical decisions,systematic evaluation,evidence summaries,expert consensus and relevant high-quality original studies,from the databases was conducted.The retrieval time period was from the establishment of the database to January 2025.Two researchers independently assessed the quality of literature and extracted evidence.Results A total of 13 articles,including one guideline,one evidence summary,4 expert consensus documents,4 randomized controlled trials(RCT),2 cross-sectional surveys,and one case report,were included in this study.A total of 4 pieces of best evidence,involving 24 aspects,were summarized.Conclusion This summary of the best evidence provides evidence-based support for the management of HCC patients receiving HAIC.It is recommended that the formulation of most appropriate management plan should be based on each patient's own condition and the environment of medical resources while transforming and applying the evidence in clinical practice.
